(Source: Enanta Pharmaceuticals Inc) Enanta Announces U.S. Food and Drug Administration Approves AbbVie's VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus VIEKIRA PAK regimen contains Enanta's lead protease inhibitor, paritaprevir (formerly ABT-450) In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than two percent of patients experiencing virological failure Tolerability profile shows more than 98 percent of patients completed a full course of therapy All oral interferon-free regimen approved for HCV/HIV-1 co-infection and patients who have undergone a liver...
↧